Inactive Instrument

Governance CymaBay Therapeutics, Inc.

CBAY

US23257D1037

Biotechnology & Medical Research

Executive Committee: CymaBay Therapeutics, Inc.

Manager

Positions heldSince

Andrew Dickinson

54 year

President	20/03/2024
Treasurer	20/03/2024

Composition of the Board of Directors: CymaBay Therapeutics, Inc.

Director

CommitteesSince

Andrew Dickinson

54 year

Director/Board Member

20/03/2024

Latest Appointments: CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc. Announces Board Changes	03-22	CI
CymaBay Therapeutics, Inc. Announces Executive Changes	01-26	CI
Cymabay Therapeutics, Chief Commercial Officer Agree to End Employment; Shares Fall After-Hours	12-21	MT
Cymabay Therapeutics, Inc. and Lewis Stuart, Chief Commercial Officer, Mutually Agrees on Cease to Be an Officer and Employee Effective December 29, 2023	12-21	CI
Cymabay Therapeutics Appoints Harish Shantharam Chief Financial Officer	09/05/23	MT
Cymabay Therapeutics, Inc. Announces Resignation of Dennis Kim as Chief Medical Officer	23/02/23	CI
CymaBay Therapeutics, Inc. Announces Executive Changes	01/11/22	CI

More news

Former Officers and Directors: CymaBay Therapeutics, Inc.

Insider

Positions held

SinceUntil

Harish Shantharam

Comptroller/Controller/Auditor	23/01/2024	21/03/2024
Director of Finance/CFO	21/05/2023	21/03/2024

Klara Dickinson-Eason

Compliance Officer	31/12/2018	-
General Counsel	25/06/2017	21/03/2024

Kurt von Emster

Director/Board Member	23/04/2009	21/03/2024
Independent Dir/Board Member	23/04/2009	21/03/2024

Robert Wills

Director/Board Member	17/03/2015	05/10/2015
Chairman	05/10/2015	21/03/2024
Independent Dir/Board Member	17/03/2015	21/03/2024

Caroline Loewy

Director/Board Member	05/12/2016	21/03/2024
Independent Dir/Board Member	05/12/2016	21/03/2024

Sujal Shah

Director/Board Member	31/05/2017	21/03/2024
Chief Executive Officer	28/03/2017	21/03/2024
Director of Finance/CFO	26/06/2012	28/03/2017
President	28/03/2017	21/03/2024
Corporate Secretary	26/06/2012	03/12/2017

Charles McWherter

Chief Tech/Sci/R&D Officer

30/06/2007

21/03/2024

Patrick J. O'Mara

Corporate Officer/Principal

31/12/1990

21/03/2024

Patricia Rohane

Corporate Officer/Principal

31/08/2018

21/03/2024

Kenneth F. Boehm

Human Resources Officer

31/03/2019

21/03/2024

Thomas Wiggans

Director/Board Member	04/04/2021	21/03/2024
Independent Dir/Board Member	04/04/2021	21/03/2024

Eric Lefebvre

Director/Board Member	20/03/2022	21/03/2024
Independent Dir/Board Member	20/03/2022	21/03/2024

Daniel Menold

Comptroller/Controller/Auditor	21/05/2023	23/01/2024
Director of Finance/CFO	31/12/2013	21/05/2023

Lewis J. Stuart

Corporate Officer/Principal

12/05/2021

28/12/2023

Dennis D. Kim

Chief Tech/Sci/R&D Officer

12/05/2021

19/02/2023

Paul Truex

Director/Board Member	31/03/2016	31/03/2021
Independent Dir/Board Member	31/03/2016	31/03/2021

Robert Booth

Director/Board Member	05/12/2016	23/01/2020
Independent Dir/Board Member	05/12/2016	23/01/2020

Robert J. Weiland

Director/Board Member	31/03/2016	23/01/2020
Independent Dir/Board Member	31/03/2016	23/01/2020

Carl Goldfischer

Director/Board Member	31/07/2003	22/01/2020
Independent Dir/Board Member	31/07/2003	22/01/2020

Evan Stein

Director/Board Member	21/03/2016	22/01/2020
Independent Dir/Board Member	21/03/2016	22/01/2020

Janet Dorling

Corporate Officer/Principal	04/08/2019	30/11/2019
Director/Board Member	04/04/2021	21/03/2024

Pol Boudes

Chief Tech/Sci/R&D Officer

31/03/2014

29/09/2019

Kirk Rosemark

General Counsel

31/03/2015

31/03/2017

Harold E. van Wart

Director/Board Member	31/12/2002	31/12/2016
Chief Executive Officer	31/12/2002	28/03/2017
Chief Operating Officer	30/11/2001	31/12/2002
Chief Tech/Sci/R&D Officer	30/09/2000	30/11/2002
President	31/12/2000	28/03/2017

Louis Lange

Director/Board Member	31/10/2003	09/11/2009
Chairman	09/11/2009	05/10/2015
Independent Dir/Board Member	31/10/2003	05/10/2015

Edward Penhoet

Director/Board Member	17/10/2010	31/05/2015
Chairman	31/10/2004	17/10/2010
Independent Dir/Board Member	31/10/2004	31/05/2015

Bonnie Charpentier

General Counsel

30/04/2007

31/12/2013

Anthony Evnin

Director/Board Member

25/09/2013

Eric Converse

Director/Board Member

23/09/2013

Hari Kumar

Director/Board Member	31/08/2012	-
Independent Dir/Board Member	31/08/2012	-

Mary Jean Stempien

Chief Tech/Sci/R&D Officer

22/06/2012

Raymond Urbanski

Chief Tech/Sci/R&D Officer

19/10/2011

31/05/2012

Paul Quinlan

General Counsel	31/12/2004	-
Compliance Officer	03/12/2017	21/03/2024
General Counsel	03/12/2017	21/03/2024
Corporate Secretary	03/12/2017	21/03/2024

Robert Chess

Director/Board Member

23/04/2009

Donald M. Hill

Director of Finance/CFO

31/03/2008

Mark Bagnall

Chief Operating Officer	31/05/2000	31/05/2007
Director of Finance/CFO	31/05/2000	31/05/2007

Diana M. Petty

Chief Administrative Officer	31/08/2006	-
Human Resources Officer	31/08/2006	-

David Karpf

Chief Tech/Sci/R&D Officer

31/12/2003

Gary Titus

Director of Finance/CFO

31/12/2001

31/12/2002

David W. Pritchard

Director of Finance/CFO

31/12/1991

31/12/1999

John E. Blume

Corporate Officer/Principal

Thomas A. Glaze

President

Patrick James Doyle

Corporate Officer/Principal

Thomas Woiwode

Director/Board Member

Robert Zerbe

Director/Board Member

25/05/2009

Kenneth L. Luskey

Corporate Officer/Principal

Bradley Bolzon

Director/Board Member

Daniel Asse van den Noort

Director/Board Member

Lynn Kozma

Corporate Officer/Principal

Bill Usinger

Chief Tech/Sci/R&D Officer

Age distribution of managers

Parity Men Women

Male	1
Female	0

Of which Executive Committee

Male	1
Female	0

Of which Directors

Male	1
Female	0

ESG Refinitiv

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar (MBX-8025), is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The Company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation.

Employees

101

Sector

Biotechnology & Medical Research

More about the company